Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Clinical and economic implications of the use of nanoparticle paclitaxel (Nanoxel) in India.

Ranade AA, Joshi DA, Phadke GK, Patil PP, Kasbekar RB, Apte TG, Dasare RR, Mengde SD, Parikh PM, Bhattacharyya GS, Lopes GL.

Ann Oncol. 2013 Sep;24 Suppl 5:v6-12. doi: 10.1093/annonc/mdt322.

PMID:
23975704
2.

Efficiency and mechanism of intracellular paclitaxel delivery by novel nanopolymer-based tumor-targeted delivery system, Nanoxel(TM).

Madaan A, Singh P, Awasthi A, Verma R, Singh AT, Jaggi M, Mishra SK, Kulkarni S, Kulkarni H.

Clin Transl Oncol. 2013 Jan;15(1):26-32. doi: 10.1007/s12094-012-0883-2. Epub 2012 Jul 24.

PMID:
22855169
3.

Adverse drug reaction profile of nanoparticle versus conventional formulation of paclitaxel: An observational study.

Brahmachari B, Hazra A, Majumdar A.

Indian J Pharmacol. 2011 Apr;43(2):126-30. doi: 10.4103/0253-7613.77341.

4.
5.

Cost comparison and economic implications of commonly used originator and generic chemotherapy drugs in India.

Lopes Gde L.

Ann Oncol. 2013 Sep;24 Suppl 5:v13-6. doi: 10.1093/annonc/mdt323.

PMID:
23975699
6.

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.

Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R.

Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. Review.

7.

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.

Forbes C, Shirran L, Bagnall AM, Duffy S, ter Riet G.

Health Technol Assess. 2001;5(28):1-110. Review.

8.

Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer.

Ando M, Yonemori K, Katsumata N, Shimizu C, Hirata T, Yamamoto H, Hashimoto K, Yunokawa M, Tamura K, Fujiwara Y.

Cancer Chemother Pharmacol. 2012 Feb;69(2):457-65. doi: 10.1007/s00280-011-1726-5. Epub 2011 Aug 19.

PMID:
21853310
9.

A multicenter phase II randomized study of Cremophor-free polymeric nanoparticle formulation of paclitaxel in women with locally advanced and/or metastatic breast cancer after failure of anthracycline.

Ranade AA, Bapsy PP, Nag S, Raghunadharao D, Raina V, Advani SH, Patil S, Maru A, Gangadharan VP, Goswami C, Sekhon JS, Sambasivaiah K, Parikh P, Bakshi A, Mohapatra R.

Asia Pac J Clin Oncol. 2013 Jun;9(2):176-81. doi: 10.1111/ajco.12035. Epub 2012 Nov 26.

PMID:
23176568
10.

Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.

Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, Esmaeli B, Ring SE, Bedikian A, Hortobagyi GN, Ellerhorst JA.

Clin Cancer Res. 2002 May;8(5):1038-44.

11.

Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.

Ward S, Simpson E, Davis S, Hind D, Rees A, Wilkinson A.

Health Technol Assess. 2007 Oct;11(40):1-144. Review.

12.
13.

Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study.

Ko YJ, Canil CM, Mukherjee SD, Winquist E, Elser C, Eisen A, Reaume MN, Zhang L, Sridhar SS.

Lancet Oncol. 2013 Jul;14(8):769-76. doi: 10.1016/S1470-2045(13)70162-1. Epub 2013 May 22.

PMID:
23706985
14.

Cost-effectiveness analysis of docetaxel versus weekly paclitaxel in adjuvant treatment of regional breast cancer in New Zealand.

Webber-Foster R, Kvizhinadze G, Rivalland G, Blakely T.

Pharmacoeconomics. 2014 Jul;32(7):707-24. doi: 10.1007/s40273-014-0154-x.

PMID:
24859241
15.

nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial.

Dranitsaris G, Coleman R, Gradishar W.

Breast Cancer Res Treat. 2010 Feb;119(3):717-24. doi: 10.1007/s10549-009-0424-z. Epub 2009 Jun 3.

PMID:
19495958
16.

Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety.

Shimada H, Ueda S, Saeki T, Shigekawa T, Takeuchi H, Hirokawa E, Sugitani I, Sugiyama M, Takahashi T, Matsuura K, Yamane T, Kuji I, Hasebe T, Osaki A.

Jpn J Clin Oncol. 2015 Jul;45(7):642-9. doi: 10.1093/jjco/hyv055. Epub 2015 May 19.

PMID:
25989989
17.

Phase I and pharmacokinetic study of ABI-007, albumin-bound paclitaxel, administered every 3 weeks in Japanese patients with solid tumors.

Yamada K, Yamamoto N, Yamada Y, Mukohara T, Minami H, Tamura T.

Jpn J Clin Oncol. 2010 May;40(5):404-11. doi: 10.1093/jjco/hyp192. Epub 2010 Feb 4.

18.

A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer.

Montero AJ, Avancha K, Gl├╝ck S, Lopes G.

Breast Cancer Res Treat. 2012 Apr;132(2):747-51. doi: 10.1007/s10549-011-1919-y. Epub 2011 Dec 27.

PMID:
22200867
19.

Efficacy and safety of metronomic administration of paclitaxel for advanced recurrent non-small-cell lung cancer.

Noronha V, Patil VM, Joshi A, Prabhash K.

Indian J Cancer. 2013 Apr-Jun;50(2):122-7. doi: 10.4103/0019-509X.117032.

20.

Survival outcome and cost-effectiveness with docetaxel and paclitaxel in patients with metastatic breast cancer: a population-based evaluation.

Vu T, Ellard S, Speers CH, Taylor SC, de Lemos ML, Hu F, Kuik K, Olivotto IA.

Ann Oncol. 2008 Mar;19(3):461-4. Epub 2007 Nov 15.

PMID:
18006892

Supplemental Content

Support Center